Open
透過自主開發的新穎性微管陣列薄膜，並結合美國國家癌症研究所開發的中空纖維測定法， 可針對藥廠提供短時間內抗癌藥物之開發及協助提高臨床二期實驗通過率；此外提供癌症病患個人化精準用藥篩選服務及提供醫師選擇抗癌藥物治療時之科學數據參考。
The MTAM-HFA is based on the US National Cancer Institute (NCI) developed technique known as the Hollow Fiber Assay (HFA). We introduce a new component known as the Microtube Array Membrane (MTAM) which consists of a whole host of beneficial microstructures which are patented. The combination of tumor cells (primary/cell line) which can be solid or non-solid, which are then siphoned into the lumens of the MTAMs; fused and subcutaneously implanted into the backs of Balb/C mice. Anti-cancer drugs (small molecule, protein, immunotherapy, cell therapy*) are administered accordingly and the entire test can be completed within 14 days.
The MTAM-HFA is based on the US National Cancer Institute (NCI) developed technique known as the Hollow Fiber Assay (HFA). We introduce a new component known as the Microtube Array Membrane (MTAM) which consists of a whole host of beneficial microstructures which are patented. The combination of tumor cells (primary/cell line) which can be solid or non-solid, which are then siphoned into the lumens of the MTAMs; fused and subcutaneously implanted into the backs of Balb/C mice. Anti-cancer drugs (small molecule, protein, immunotherapy, cell therapy*) are administered accordingly and the entire test can be completed within 14 days.